The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Glucocorticoid (GC)-free resolution of polymyalgia rheumatica (PMR) signs and symptoms in patients treated with sarilumab with history of flare: analysis from SAPHYR
The poster reports post-hoc results from the SAPHYR study on the resolution of PMR signs and symptoms regardless of glucocorticoid (GC) use and GC-free resolution of PMR signs and symptoms over time. GC-free resolution of PMR signs and symptoms was maintained from week 16 to week 52 in majority of patients treated with sarilumab 200mg Q2W + 14week GC.